| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
a modern antidiabetic agent which is weight neutral and associated with
low rate of hypoglycaemias, is being increasingly used in type 2
diabetes mellitus (DM). However, there is a paucity of data about its
efficacy and safety in beta-thalassaemia major (β-TM).
|Table 1. Demographic characteristics and iron chelation therapy|
|Table 2. Longitudinal changes in fructosamine, weight and ferritin|